Abstract
A cachexia diagnosis is associated with a doubling in hospital stay and increased healthcare cost for cancer patients and most cachectic patients do not survive treatment. Unfortunately, complexity in treating cachexia is amplified by both the underlying malignancy and the anti-cancer therapy which can independently promote cachexia. Quercetin, an organic polyphenolic flavonoid, has demonstrated anti-inflammatory and antioxidant properties with promise in protecting against cancer and chemotherapy-induced dysfunction; however, whether quercetin is efficacious in maintaining muscle mass in tumor-bearing animals receiving chemotherapy has not been investigated. C26 tumor-bearing mice were given 5-fluorouracil (5FU; 30 mg/kg of lean mass i.p.) concomitant with quercetin (Quer; 50 mg/kg of body weight via oral gavage) or vehicle. Both C26 + 5FU and C26 + 5FU + Quer had similar body weight loss; however, muscle mass and cross-sectional area was greater in C26 + 5FU + Quer compared to C26 + 5FU. Additionally, C26 + 5FU + Quer had a greater number and larger intermyofibrillar mitochondria with increased relative protein expression of mitochondrial complexes V, III, and II as well as cytochrome c expression. C26 + 5FU + Quer also had increased MFN1 and reduced FIS1 relative protein expression without apparent benefits to muscle inflammatory signaling. Our data suggest that quercetin protected against cancer and chemotherapy-induced muscle mass loss through improving mitochondrial homeostatic balance.
Funder
National Institutes of Health’s National Center for Complementary and Integrative Health
Subject
Food Science,Nutrition and Dietetics
Reference63 articles.
1. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA;Arthur;Drugs Context,2014
2. Prevalence, incidence and clinical impact of cachexia: Facts and numbers-update 2014;Anker;J. Cachexia Sarcopenia Muscle,2014
3. Cachexia among US cancer patients;Arthur;J Med. Econ.,2016
4. Survival prediction in terminal cancer patients: A systematic review of the medical literature;Vigano;Palliat. Med.,2000
5. Sealy, M.J., Dechaphunkul, T., van der Schans, C.P., Krijnen, W.P., Roodenburg, J.L.N., Walker, J., Jager-Wittenaar, H., and Baracos, V.E. (2019). Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin. Nutr.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献